LTS Lohmann Therapie-Systeme AG (LTS) has announced the acquisition of Renaissance Lakewood ("Renaissance"), a US-based contract development and manufacturing organisation (CDMO) specialising in nasal sprays and sterile dosage forms.
Renaissance facilities will become part of LTS's worldwide operations network, alongside its existing facilities in Andernach, Germany, West Caldwell, NJ, US, St Paul, MN, US and Netanya, Israel.
The acquisition of Renaissance marks a significant milestone in LTS's strategy to expand its capabilities in the CDMO space.
Renaissance brings deep expertise, state-of-the-art manufacturing infrastructure and a talented workforce of around 500 employees.
This move enables LTS to offer a broader range of drug delivery solutions, strengthening its position within the CDMO community.
Founded in 1979 and currently owned by RoundTable Healthcare Partners, Renaissance is headquartered in Lakewood, New Jersey.
The company operates multiple manufacturing suites for unit-dose, bi-dose, multi-dose nasal sprays and small-volume parenteral fill-finish vials.
Its laboratories support R&D formulation development and spray characterisation, making Renaissance a comprehensive partner from development through commercial launch.
This acquisition aligns with LTS's commitment to innovation and excellence in drug delivery.
By integrating Renaissance's capabilities, LTS will be better positioned to serve pharmaceutical and biotech partners across a wider spectrum of therapeutic modalities.
Bas van Buijtenen, CEO of LTS, commented: "We are delighted to welcome Renaissance Lakewood to the LTS family."
"This acquisition marks a significant step in our strategy to expand our CDMO capabilities and strengthen our position as a global leader in innovative drug delivery solutions."
"Renaissance's expertise in nasal sprays and sterile dosage forms perfectly complements our existing portfolio and will enable us to offer even greater value to our partners and patients worldwide."
"We look forward to working together to drive innovation and deliver high-quality solutions across a broader range of therapeutic modalities."
Serge Maltais, President & CEO of Renaissance, added: "I am incredibly proud of what we have built at Renaissance thanks to the hard work and dedication of our employees."
"Now, as part of the LTS family, our combined strengths will position us even better to meet the complex needs of our clients and deliver greater value to the industry."
"We are excited to begin this new chapter and look forward to achieving success together."
The transaction is expected to close before the end of November 2025, subject to regulatory approvals.